[1] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009; 27, 6550−7. doi:  10.1016/j.vaccine.2009.08.048
[2] Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J, 2009; 122, 3−4.
[3] Jiang W, Liu T, Dong H, et al. Relationship between serum DNA replication, clinicopathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by lamivudine plus adefovir dipivoxil combination therapy. Biomed Environ Sci, 2015; 28, 206−13.
[4] Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol, 2014; 25, 1137−9. doi:  10.1681/ASN.2014010091
[5] D Hui, X Yan, J Wei, et al. Significance of mutations in hepatitis B virus X gene for the pathogenesis of HB-associated glomerulonephritis. Acta virologica, 2014; 58, 278−81. doi:  10.4149/av_2014_03_278
[6] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet Lond Engl, 2015; 386, 1546−55. doi:  10.1016/S0140-6736(15)61412-X
[7] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC Med, 2018; 16, 93−100. doi:  10.1186/s12916-018-1084-9
[8] Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009; 361, 11−21. doi:  10.1056/NEJMoa0810457
[9] Hoxha E, Ursula K, Gesa S, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomemli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int, 2012; 82, 797−804. doi:  10.1038/ki.2012.209
[10] Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant, 2013; 28, 1839−44. doi:  10.1093/ndt/gfs439
[11] Xie QH, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol, 2015; 41, 345−53. doi:  10.1159/000431331
[12] Chun E, Lee J, Cheong HS, et al. Tumor eradication by hepatitis B virus X antigen-specific CD8+ T cells in xenografted nude mice. J Immunol, 2003; 170, 1183−90. doi:  10.4049/jimmunol.170.3.1183
[13] Hwang GY, Huang CJ, Lin CY, et al. Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen. Virus Res, 2003; 92, 157−64. doi:  10.1016/S0168-1702(03)00043-1
[14] Zhu R, Zhang HP, Yu H, et al. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients. Pathol Res Pract, 2008; 204, 731−42. doi:  10.1016/j.prp.2008.05.001